Siglec-15: An Attractive Immunotherapy Target.
Siglec-15, which selectively drives immunosuppression in the tumor microenvironment, has emerged as a viable therapeutic target. In a phase I trial of NC318, a Siglec-15 antibody, encouraging efficacy was seen, including a complete response in non-small cell lung cancer refractory to PD-1 blockade.